Ignite Creation Date:
2025-12-18 @ 9:03 AM
Ignite Modification Date:
2025-12-18 @ 9:03 AM
Study NCT ID:
NCT06099782
Status:
Last Update Posted:
First Post:
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Sponsor:
Organization: